NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 26 to 50 of 1245

Display Results as:

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01 Clinical Trial Optional) - PA-18-284

Organization: NIMHD 

Posting Date: 11-01-2017 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to develop and implement effective interventions to address health disparities among U.S. immigrant populations.  

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R21 Clinical Trial Optional) - PA-18-285

Organization: NIMHD 

Posting Date: 11-01-2017 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate innovative exploratory and developmental research to develop and test feasibility of effective interventions to address health disparities among U.S. immigrant populations.  

Addressing Unmet Needs in Persons with Dementia to Decrease Behavioral Symptoms and Improve Quality of Life (R01 Clinical Trial Optional) - PA-18-147

Organization: NINR 

Posting Date: 11-07-2017 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research addressing behavioral and psychological symptoms of dementia (BPSD) and the association of BPSD with unmet physical, social, or environmental needs in persons with dementia. 

Addressing Unmet Needs in Persons with Dementia to Decrease Behavioral Symptoms and Improve Quality of Life (R21 Clinical Trial Optional) - PA-18-165

Organization: NINR 

Posting Date: 11-07-2017 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research addressing behavioral and psychological symptoms of dementia (BPSD) and the association of BPSD with unmet physical, social, or environmental needs in persons with dementia. 

Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional) - PAR-18-747

Organization: NIMHD 

Posting Date: 04-10-2018 

Expiration Date: 11-14-2020 

Activity Code: R01 

Summary: This funding opportunity announcement (FOA) seeks to support investigative and collaborative research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations. 

Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional) - PAR-18-745

Organization: NIMHD 

Posting Date: 04-10-2018 

Expiration Date: 11-14-2020 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations. 

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01) - PA-17-041

Organization: NIMHD 

Posting Date: 11-01-2016 

Expiration Date: 01-08-2020 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.  

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R21) - PA-17-042

Organization: NIMHD 

Posting Date: 11-01-2016 

Expiration Date: 01-08-2020 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory and developmental research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations  

Administrative Supplement for the NIBIB Research Education Programs for Residents and Clinical Fellows (Admin Supp Clilnical Trial Not Allowed) - PA-18-680

Organization: NIBIB 

Posting Date: 02-23-2018 

Expiration Date: 03-18-2020 

Activity Code: (Admin Supp) 

Summary: This FOA is to be used to request administrative supplements for awards made to PAR-12-085 and PAR-15-167 "NIBIB Research Education Programs for Residents and Clinical Fellows program". This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. 

Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp) - PA-17-442

Organization: NINDS 

Posting Date: 07-28-2017 

Expiration Date: 10-16-2019 

Activity Code: (Admin Supp) 

Summary: This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)  

Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supp) - PA-16-013

Organization: NCCIH  (formerly NCCAM)

Posting Date: 10-26-2015 

Expiration Date: 09-02-2018 

Activity Code: (Admin Supp) 

Summary: NCCIH encourages applications for administrative supplements to NCCIH-supported awards (see relevant Activity Codes above) to support complementary health practitioners in an intensive supervised clinical research experience that will lead to a better understanding of and practical experience in complementary and integrative health research. For this FOA, clinicians may include (but are not limited to) licensed acupuncturists, chiropractors, naturopathic medicine practitioners, and massage therapists. Funding is available for one year with an option to renew for a second year. to conduct clinical research associated with the parent program. This initiative is focused on providing a research experience for complementary health practitioners and is not intended to support clinical residency training or other clinical practitioner training. 

Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp - Clinical Trial Not Allowed) - PA-18-702

Organization: NIBIB 

Posting Date: 03-06-2018 

Expiration Date: 08-02-2018 

Activity Code: (Admin Supp) 

Summary: The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying. 

Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp) - PA-18-713

Organization: NIH 

Posting Date: 03-15-2018 

Expiration Date: 05-08-2018 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) Office of the Director announces the availability of administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) are notified that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. SGM populations include, but are not limited to, lesbian, gay, bisexual, and transgender people, and individuals with differences or disorders of sexual development (sometimes referred to as intersex or as specific diagnoses). This trans-NIH effort, which involves multiple Institutes, Centers and Offices from across NIH, is intended to encourage investigation in this growing, field of research. To increase our collective understanding of the broad range of research needed to address the unique health issues of SGM populations, the supplement will focus on areas of research interest, including, but not limited to: studies on increased disease risk; mental, behavioral and social health; approaches to personalized medicine; access to care; reprod 

Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supplement) - PA-17-326

Organization: NINDS 

Posting Date: 07-18-2017 

Expiration Date: 09-19-2019 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) announces the continuation of the U.S. entity of the U.S.-Japan Brain Research Cooperative Program (BRCP). This administrative supplement program will provide funds to research projects that are currently supported by the participating NIH Institutes and Centers. 

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional) - PA-18-591

Organization: NIH 

Posting Date: 01-25-2018 

Expiration Date: 01-26-2021 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm. 

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) - PAR-18-752

Organization: NCI 

Posting Date: 04-11-2018 

Expiration Date: 07-01-2018 

Activity Code: (Admin Supp) 

Summary: This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials. 

Administrative Supplements to NIGMS Predoctoral Training Grants for the Development of Activities to Prepare Trainees for Careers in the Biomedical Research Workforce (Admin Supp Clinical Trial Not Allowed) - PA-18-757

Organization: NIGMS 

Posting Date: 04-17-2018 

Expiration Date: 05-19-2018 

Activity Code: (Admin Supp) 

Summary: The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of activities aimed at broadening the training experience to better prepare individuals for careers in the biomedical research workforce.). 

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) - RFA-CA-18-005

Organization: NCI 

Posting Date: 11-20-2017 

Expiration Date: 09-29-2018 

Activity Code: R33 

Summary: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. 

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) - RFA-CA-18-003

Organization: NCI 

Posting Date: 11-20-2017 

Expiration Date: 09-29-2018 

Activity Code: R33 

Summary: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are non-responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.  

Advanced Development of Informatics Technologies for Cancer Research and Management (U24) - PAR-15-331

Organization: NCI 

Posting Date: 08-18-2015 

Expiration Date: 11-21-2018 

Activity Code: U24 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.  

Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional) - PAR-18-701

Organization: NIMH 

Posting Date: 03-05-2018 

Expiration Date: 05-19-2020 

Activity Code: P50 

Summary: This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within diverse care systems. The ALACRITY Centers program is intended to support research that demonstrates an extraordinary level of synergy across disciplines and has a high potential for increasing the public health impact of existing and emerging mental health interventions and service delivery strategies. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to provide opportunities for graduate students, postdoctoral researchers, and new investigators to participate in transdisciplinary, T2 translational mental health research. 

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 - Clinical Trial Optional) - PAR-18-644

Organization: NIA 

Posting Date: 02-08-2018 

Expiration Date: 09-08-2019 

Activity Code: R33 

Summary: This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. 

Advances in Patient Safety through Simulation Research (R18) - PA-16-420

Organization: AHRQ 

Posting Date: 09-06-2016 

Expiration Date: 01-26-2022 

Activity Code: R18 

Summary: The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed. 

Advances in Polycystic Kidney Disease (R01) - PA-16-159

Organization: NIDDK 

Posting Date: 03-30-2016 

Expiration Date: 05-08-2019 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of Polycystic Kidney Disease (PKD), in both its autosomal dominant and autosomal recessive forms.The ultimate aim is to facilitate PKD-related research studies, which will provide the basis for new therapeutic approaches.  

Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed) - PAR-18-505

Organization: NIMH 

Posting Date: 12-18-2017 

Expiration Date: 01-08-2021 

Activity Code: R01 

Summary: This funding opportunity announcement (FOA) encourages research grant applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top